Merck & Co. Stories
World Market Update 22/03/2011
U.S. stocks surged on Monday as sentiment was buoyed after Japan made progress in its battle to control radiation leaks at a crippled plant, and AT&T announced that it will buy T-Mobile USA from German company Deutsche Telekom to create the largest mobile provider in the United States.
Retailers lead market gains ahead of jobs data
Stocks ended near the session's highs on Thursday, with investors favoring shares of retailers after encouraging chain-store sales raised confidence ahead of Friday's jobs report.
U.S. stocks down slightly so far in the wake of cautious speech by Bernanke
Retail clothing stores such as Ann Taylor are leading the way so far on strong retail report by the Institute for Supply Management
Wall St slips on Egypt concerns
U.S. stocks slipped on Thursday as concerns over increasing disorder in Egypt and signs of exhaustion in the recent market rally weighed on investor sentiment.
Merck yanks long-term view, CEO says to protect R&D
Merck & Co warned investors that it could no longer vouch for its long-term profit forecast due to pressure to curb prices on its drugs and dimmed hopes for an experimental blood clot treatment.
Wall St slips as rally loses steam
U.S. stocks slipped on Thursday as concerns over increasing disorder in Egypt and signs of exhaustion in the recent market rally weighed on investor sentiment.
Wall Street rally fading as Egypt concerns mount
Wall Street tumbled on Thursday as concerns over increasing disorder in Egypt and signs of exhaustion in the recent market rally weighed on investor sentiment.
Wall St edges lower as Egypt unrest weighs
U.S. stocks opened slightly lower on Thursday as investors weighed hints of an improving economy against increasing disorder in Egypt and signs pointing to an end to the recent rally.
Stock futures edge lower ahead of factory, jobs data
U.S. stock index futures edged lower on Thursday as investors weighed the prospects of some solid U.S. economic data against increasing discord in Egypt and worries that a rally that may be losing steam.
Scientists find inflammation immune cell switch
Scientists have found a protein that acts as a master switch to determine whether certain white blood cells will boost or dampen inflammation, a finding that may help the search for new drugs for rheumatoid arthritis.
Merck, materials companies drag Wall Street lower
Stocks edged lower on Thursday, hurt by a slide in drugmaker Merck and as falling commodities prices hit shares of natural resource companies.
Stocks edged down on a disappointing labor market data
Stocks edged down on a disappointing labor market data
Merck weighs on Dow, market eyes earnings
The Dow industrials fell on Thursday, hurt by a slide in Merck shares, but the market was near 28-month highs as investors saw stocks' upward trend continuing despite disappointing jobless claims data.
Market flat on weak jobless claims
U.S. stocks barely budged on Thursday as investors looked past disappointing jobless claims while a jump in Marathon Oil's shares boosted the oil sector.
Market flat, pares losses from jobless claims
U.S. stocks were little changed on Thursday, paring losses after weaker-than-expected jobless claims and helped by a rise in Marathon Oil.
Medtronic CEO to retire; outside search started
Medtronic Inc Chief Executive Officer William Hawkins plans to retire in April after a tenure of more than three years in which the medical device maker's stock performance disappointed investors.
Pfizer CEO change could signal strategic switch
Investors hoped a leadership shake-up at Pfizer Inc might bring divestitures, share buybacks or other moves to kick-start the company's sluggish stock price, but they were wary of disruption stemming from the abrupt change.
Pfizer's Kindler steps down as chief executive, replaced by Ian Read
Pfizer Inc. announced that its chief executive Jeffrey Kindler has retired from the company and he will be replaced by Ian Read, currently head of its global biopharmaceutical operations.
Pfizer CEO Jeffrey Kindler retires, replaced by Read
The chief executive officer of Pfizer Inc,, the world's largest drugmaker, retired in an unexpected move to recharge his batteries after completing the mega merger with rival Wyeth.
Merck ends late stage Isentress study in HIV patients
Pharma giant Merck said it discontinued Isentress once daily study in treatment-naïve adult HIV-1 patients after it failed to show non-inferiority to the treatment regimen that included Isentress twice daily.
Common bone drugs increases risk of esophageal cancer
A recent study states that people taking a commonly used class of osteoporosis drugs called bisphosphonates for more than five years may be doubling their risk of developing cancer of the gullet or esophagus.
Common bone drugs linked to esophageal cancer risk
People who take a commonly used class of osteoporosis drugs called bisphosphonates for more than five years may be doubling their risk of developing cancer of the gullet or esophagus, a British study found on Friday.
Drug combination helped kill deadly cancer in mice
Adding an experimental drug to chemotherapy helped wipe out brain cancer cells in mice, offering a promising new treatment approach for the deadly cancer, U.S. researchers said on Tuesday.
Merck pares 2010 forecast, despite beat in quarter
Merck and Co issued a more cautious 2010 profit outlook on Friday and reported disappointing second-quarter sales of its vaccines and Singulair asthma drug, sending its shares down 2 percent.
Wall Street falls on GDP and earnings
Wall Street stocks fell on Friday after weak economic growth figures for the second quarter and disappointing earnings from Merck painted an uncertain outlook for the rest of the year.
Merck profit beats Wall Street view
Merck & Co reported higher-than-expected second-quarter earnings on Friday, helped by strong sales of its treatments for diabetes, arthritis and
HIV.
Stock futures slip ahead of GDP data
Wall St stock index futures pointed to a lower start on Friday as investors stayed cautious ahead of U.S. GDP data, with S&P 500, Dow Jones and Nasdaq futures down 0.3 to 0.4 percent at 5:11 a.m. ET.
Common blood pressure drugs may raise cancer risk
A widely used class of blood pressure drugs may slightly increase the risk of cancer, U.S. researchers said on Sunday, and they are calling on U.S. regulators to take a closer look.
Pfizer and Merck post profit, revenue above targets
U.S. drugmakers Pfizer Inc and Merck & Co posted better-than-expected first-quarter profit and revenue on Tuesday, but Merck gave a 2010 earnings forecast that could fall short of Wall Street's target.
Wall Street set for lower open as Greece worries linger
U.S. stocks were set for a sharply lower open on Tuesday as Greece's debt problems continued to rattle investors and after a broad rally in the previous session that took the S&P 500 to its biggest day in two months.